ISSN 1662-4009 (online)

ey0018.10-11 | (1) | ESPEYB18

10.11. Use of factory-calibrated real-time continuous glucose monitoring improves time in target and HbA1c in a multiethnic cohort of adolescents and young adults with type 1 diabetes: the MILLENNIALS study

H Thabit , JN Prabhu , W Mubita , C Fullwood , S Azmi , A Urwin , I Doughty , L Leelarathna

Diabetes Care. 2020;43(10):2537–2543. doi: 10.2337/dc20-0736.This paper describes a randomized crossover trial in young people with T1D (16–24 years old) comparing two 8-week study periods: the factory-calibrated Dexcom G6 CGM system versus routine self-monitoring of blood glucose (SMBG). CGM improved time within glucose target and reduced HbA1c by 0.76%.The prim...

ey0020.13-5 | Section | ESPEYB20

13.5. Intermittently scanned continuous glucose monitoring for type 1 diabetes

L Leelarathna , ML Evans , S Neupane , G Rayman , S Lumley , I Cranston , P Narendran , K Barnard-Kelly , CJ Sutton , RA Elliott , VP Taxiarchi , G Gkountouras , M Burns , W Mubita , N Kanumilli , M Camm , H Thabit , EG Wilmot , FLASH-UK Trial Study Group

In Brief: This multicenter, randomised controlled trial in 156 adults (mean age 44 years) with type 1 diabetes (T1D) showed benefits of intermittently scanned continuous glucose monitoring (CGM) (intervention) compared to usual monitoring of blood glucose levels by fingerprick testing on: lower HbA1c (−0.5%; P<0.001), 130 minutes/day longer duration of ‘in target’ glucose levels, and 43 minutes/day shorter time spent with hypoglycaemic blood glucos...